On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
Working with numerous partners, DiMe has introduced the 3Ps of Digital Endpoint Value to help inclusion of digital endpoints in drug reimbursement decisions.
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimer’s drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
Acting US FDA commissioner, Janet Woodcock, has called for an independent federal review of interactions between officials at her agency and representatives of Biogen, prior to the recent approval of the pharma company’s treatment for Alzheimer’s disease....
The US Food and Drug Administration (FDA) has approved Biogen’s Aduhelm (aducanumab) for the treatment of Alzheimer’s: making it the first new treatment approved for the disease since 2003.
As a day of climate strikes unfolds across the world, we ask how far pharma is engaged on the issue, as well as noting recent innovations that suggest companies are looking at what can be done.
The multi-stakeholder group is developing a blockchain-powered platform to increase transparency and collaboration in the clinical trial supply chain – and has successfully completed a proof-of-concept project, now looking to next steps.
Skyhawk enters an agreement with Merck to discover and develop small molecules to modulate RNA splicing, and expands its existing development agreement with Biogen.
Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division.
Researchers from the Clinic for Special Children have developed a drug delivery catheter system that could reach a larger population of patients receive Biogen’s Spinraza treatment.
US contract manufacturer Catalent Pharma Solutions has leveraged
its partnership with Secure Symbology (SSI) for track and trace
barcode technology to help biopharmaceutical company Biogen Idec
comply with California's pending...
With a number of companies competing in the race to develop the
first oral treatment option for multiple sclerosis, UCB and Biogen
Idec's oral version of the infamous Tysabri has entered Phase II
trials.
Biogen has revealed details of a potential new pathway in
rheumatoid arthritis (RA) that could provide unique insights into
the disease process and eventually a new approach to developing RA
therapies.
The resurgence of merger and acquisition activity in the biotech
industry shows little sign of letting up, with US companies IDEC
Pharmaceuticals and Biogen the latest to step up to the altar
US biotechnology company Biogen has decided to postpone
construction of a large production plant at Hillerød in Denmark,
just three months after breaking ground on the facility
Biotechnology company Biogen this week celebrated its 25th
anniversary by breaking the ground on a large-scale manufacturing
facility in Hillerød, Denmark, marking the company's first
development phase for the region and a greater...
